MedTrace Logo

Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib

NCT00203424 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2016-03-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.

Conditions

Interventions

DRUG

Erlotinib + Bevacizumab

Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Translational Oncology Research International

    lead OTHER

Principal Investigators

  • Fairooz Kabbinavar, MD · Chief Medical Officer, TORI

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2009-02-28
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00203424 on ClinicalTrials.gov